NEW YORK (GenomeWeb) – Although next-generation sequencing is increasingly being used in a wide array of clinical settings — including noninvasive prenatal screening, in cancer care to identify potential therapies, to diagnose rare and unknown disorders, and to assess disease risk for some inheri
NEW YORK (GenomeWeb) – The Netherlands is in the midst of a nationwide study of noninvasive prenatal testing to provide it with the scientific data needed to help decide whether and how to implement the test as part of the country's prenatal screening program.
NEW YORK (GenomeWeb) – Foundation Medicine said this week that employees of Google will have covered access to its next-generation sequencing-based tumor profiling tests beginning Jan. 1, 2015.
The Baylor College of Medicine has named Matthew Ellis the newest McNair Scholar, a program that identifies researchers in breast and pancreatic cancer, juvenile diabetes, and neuroscience.
WuXi PharmaTech's Genome Center is now offering analysis services from NextCode Health, a bioinformatics company in Cambridge, Mass., which will provide population-scale genome analysis.
NEW YORK (GenomeWeb) – GeneSegues Therapeutics this week announced that it has received a $1 million contract from the National Cancer Institute to continue development of its gene-silencing cancer therapeutic GS-10.
Look out next week for a major GenomeWeb redesign that will include a change to our weekly premium newsletters. Pharmacogenomics Reporter will no longer publish on Wednesdays. Instead, you'll receive the Companion Diagnostics Bulletin, one of 10 new weekly topic-specific news mailings that will be available to all GenomeWeb Premium subscribers. You will be able to opt into any of the weekly mailings that you choose, so please visit your My Account page next week to set your email preferences!
Originally published Nov. 11.
NEW YORK (Genomeweb) — A study comprehensively analyzing the genomes of more than 1,500 neuroblastoma cases has better determined the prognostic significance of ALK mutations and other alterations in neuroblastoma, and has biochemically investigated many of these variants to determine which ones